Industry withdrawal from psychiatric medication development | JoVE Visualize

Area of Science:

Neuroscience
Psychiatry
Pharmacology

Background:

Psychiatric drug development flourished from 1950-1969 but has since declined, with a focus on "me-too" drugs over novel molecular entities.
Industry withdrawal from psychiatric medication development is driven by failing profitability and reduced patient-clinician contact, hindering observation of unexpected benefits.
Current randomized, parallel-groups designs meet efficacy requirements but do not clarify if patient improvement is drug-induced or spontaneous, obscuring pathophysiology benefits.

Purpose of the Study:

To critically evaluate current methodologies in psychiatric drug development and their limitations in understanding therapeutic benefits.
To highlight the inadequacy of existing research designs in elucidating the relationship between psychotropic drugs, pathophysiology, and patient outcomes.
To advocate for alternative research designs, specifically the intensive design, for advancing the understanding of psychiatric diagnosis, treatment, and brain pathophysiology.

Main Methods:

Review of historical trends in psychiatric drug development, from the "golden age" to the present decline.
Analysis of the limitations of the standard randomized, parallel-groups design in psychiatric research.
Emphasis on the potential utility of the intensive design for psychiatric research.

Main Results:

A significant decline in the development of novel psychiatric medication classes since the 1970s.
The current research paradigm fails to adequately determine drug efficacy versus natural patient recovery.
Understanding of the underlying brain pathophysiology and its interaction with therapeutic benefits remains limited.

Conclusions:

The "bench to bedside" claim in psychiatric therapeutic knowledge is largely unsubstantiated due to a poor understanding of brain pathophysiology.
Major psychotropic drugs demonstrate benefits likely linked to specific pathophysiological states, making studies in normal subjects unlikely to yield therapeutic insights.
An intensive study design is crucial for advancing the understanding of diagnosis, therapeutic benefit, and pathophysiology in psychiatry.